Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5'-Guanylylmethylenebisphosphonate is a synthetic, non-hydrolyzable analog of guanosine triphosphate (GTP), in which the oxygen atom bridging the beta and gamma phosphates is replaced by a methylene group. This modification makes it resistant to enzymatic hydrolysis by GTPases. It is primarily used as an experimental tool in biochemical and molecular biology research to study G-protein signaling, ribosomal function, and nucleotide-binding proteins. By mimicking GTP but resisting hydrolysis, it can lock proteins such as G-proteins or translation factors in their active or inactive states for mechanistic studies[1][2][3]. There are no approved therapeutic indications for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5'-guanylylmethylenebisphosphonate.